0000899243-23-016491.txt : 20230626 0000899243-23-016491.hdr.sgml : 20230626 20230626164619 ACCESSION NUMBER: 0000899243-23-016491 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230622 FILED AS OF DATE: 20230626 DATE AS OF CHANGE: 20230626 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Session R.A. II CENTRAL INDEX KEY: 0001701846 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39536 FILM NUMBER: 231042937 MAIL ADDRESS: STREET 1: C/O AVEXIS, INC. STREET 2: 2275 HALF DAY ROAD, SUITE 200 CITY: BANNOCKBURN STATE: IL ZIP: 60015 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Taysha Gene Therapies, Inc. CENTRAL INDEX KEY: 0001806310 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 843199512 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3000 PEGASUS PARK DRIVE STREET 2: SUITE 1430 CITY: DALLAS STATE: TX ZIP: 75247 BUSINESS PHONE: (214) 612-0000 MAIL ADDRESS: STREET 1: 3000 PEGASUS PARK DRIVE STREET 2: SUITE 1430 CITY: DALLAS STATE: TX ZIP: 75247 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-06-22 0 0001806310 Taysha Gene Therapies, Inc. TSHA 0001701846 Session R.A. II 7318 MORTON STREET DALLAS TX 75209 0 0 1 0 0 Common Stock 2023-06-22 4 S 0 10508 0.7027 D 8975719 D Common Stock 2023-06-23 4 S 0 18100 0.7036 D 8957619 D Common Stock 141090 I See footnote Common Stock 141090 I See footnote The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.70 - $0.7185. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.70 - $0.716. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The securities are held by RA Session II, as Trustee of the Session 2020 Annuity Trust I. The securities are held by RA Session II, as Trustee of the Session 2020 Annuity Trust II. /s/ R.A. Session II 2023-06-26